This clinical trial evaluates the impact of the Cancer Tracking System (CATSystem) on cervical cancer (CC) screening, referrals and treatment of women in Kenya. The CATSystem is an internet-based system that tracks and highlights patients with overdue services or those in need of outreach. The system will send automated messages and customized texts to support screening and treatment follow-up per national guidelines. The CATSystem serves as a single, linked medical record for a patient’s CC care and it’s technology has the ability to extend the reach of expert providers into remote areas. The CATSystem may increase CC screening, referrals and treatment and improve CC care of women in Kenya.
Additional locations may be listed on ClinicalTrials.gov for NCT06286462.
Locations matching your search criteria
United States
Kansas
Kansas City
University of Kansas Cancer CenterStatus: Approved
Contact: Sarah F. Kessler
PRIMARY OBJECTIVES:
I. Implement and evaluate the efficacy of the CATSystem to improve guideline adherent CC screening, treatment, referral, and follow-up.
II. Assess the feasibility and acceptability of CATSystem implementation in government hospitals.
III. Calculate costs and cost-effectiveness of the CATSystem to improve quality-adjusted life years gained.
OUTLINE:
AIM 1: Hospitals are randomized to 1 of 2 arms. Patients are assigned to 1 of 2 arms based on hospital assignment.
ARM I (INTERVENTION HOSPITALS): Hospital providers receive access to CATSystem dashboard. Patients undergo standard of care CC screening, and those with abnormal results may receive referral and treatment per standard of care for the facility. Patients also receive text message reminders to return to the hospital for appointments. Providers receive alerts if patients miss an appointment.
ARM II (CONTROL HOSPITALS): Hospital staff collect standard paper CC screening and treatment uptake data, and study staff enter data into a parallel ‘look-alike CATSystem’ on study. Patients with abnormal CC screening results may receive referral and treatment per standard of care for the facility.
AIM 2: Providers and participants with positive screening results participate in focus groups over 30-45 minutes on study.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationUniversity of Kansas Cancer Center
Principal InvestigatorSarah F. Kessler